Apollo Proton Cancer Centre Unveils India’s First Integrated Organ and Disease-Specific Programme for Management of Rectal Cancer.

Apollo Proton Cancer Centre (APCC) has launched the Apollo Rectal Cancer (ARC) Programme, India’s pioneering approach dedicated to rectal cancer management. With a focus on rectal preservation and powered by advanced technologies including chemoradiotherapy, proton therapy, and robotic surgery, the ARC programme aims to revolutionize the treatment of rectal cancer in the country. This unique initiative addresses the specialized needs of rectal cancer patients, providing comprehensive and multidisciplinary care to ensure the best possible outcomes.

The ARC programme center was inaugurated by Dr. Prathap C Reddy, Founder and Chairman, Apollo Hospitals Enterprise Ltd. (AHEL), in the presence of Mr. Harshad Reddy, Director – Group Oncology & International (AHEL). The programme will be led by Dr. Venkatesh Munikrishnan (Lead), Consultant Colorectal & Robotic Surgeon, Dr Senthil Ganapathi, Senior Consultant Colorectal Surgeon, Dr Sudeepta Kumar Swain, Consultant-Surgical Gastroenterology and Dr Bala Murugan Srinivasan, Consultant- Surgical Gastroenterology.

Dr Prathap C Reddy, Founder- Chairman, Apollo Hospitals Enterprise Ltd, said, “This groundbreaking initiative underscores our commitment to innovation and transformative cancer care in the country & globally. This is the first time in India that we have a subspecialized team of surgeons in rectal cancer surgery who will only be involved with the management of a single organ and a single type of cancer: rectal cancer. This is going to set the global benchmark of how rectal cancer will be managed in the future. Our innovative technologies continually reshape the Oncology landscape, driven by an integrative approach that combines domestic excellence and international collaborations.”

Mr Harshad Reddy, Director – Group Oncology & International, Apollo Hospitals, said, “The launch of the Apollo Rectal Cancer Programme marks a significant milestone in our commitment to advancing cancer care in India. This innovative and specialized approach reflects our dedication to providing the best possible treatment options for patients with rectal cancer, ensuring access to world-class care and achieving optimal patient outcomes. India faces a mounting burden of rectal cancer, with a forecasted 80% increase in numbers within the next decade. In response to this pressing need, this Programme stands as a pioneering initiative to provide accessible and comprehensive rectal cancer care, elevating India’s capabilities in managing this complex disease.”

Read more about the Apollo Rectal Cancer (ARC) Programme